Our Leadership

AltruBio’ senior management is built on a team of individuals possessing strong academic knowledge, high-level managerial experience and scientific expertise in a range of fields including life science, pharmacology, healthcare and immunology.

Patrick Y. Yang, Ph.D.

Chairman of the Board

Dr. Pat Yang is Executive Chairman, AltruBio. In addition to serving on corporate boards, he also works as an independent consultant in the Biopharmaceutical industry. He is executive vice chairman of National Resilience, Inc., a privately held biotech manufacturing technology company.

Most recently, Dr. Yang worked at Juno Therapeutics in Seattle as Executive Vice President from September 2017 to January 2019.

Previously, Dr. Yang was Roche’s Global Head of Technical Operations in Switzerland from 2009 to 2013. In this role, he was responsible for Roche’s biopharmaceutical process development, engineering, quality, technical regulatory, supply chain and manufacturing. Before that, he was executive vice president, Product Operations of Genentech, Inc. from 2003 to 2013. Prior to joining Genentech, Dr. Yang served for 11 years at Merck & Company in New Jersey in various leadership positions including vice president of Asia Pacific Operations and vice president of Global Supply Chain Management. Prior to joining Merck in 1992, Dr. Yang spent 12 years at General Electric, serving in several research, engineering, technology, and manufacturing leadership roles with increasing scope of responsibilities. Before GE, Dr. Yang spent five years in aerospace control systems research and development with Life Systems, Inc.

Dr. Yang holds a Bachelor of Science from the National Chiao Tung University in Taiwan, a Master of Science from the University of Cincinnati, and a doctorate in engineering from Ohio State University, Columbus, Ohio. Dr. Yang is a member of Board of Directors for three public companies: Codexis, Sana Biotech, and PharmaEssentia. He also serves on the corporate boards of several private companies including Acepodia, Archigen Biotech, and Antheia. He previously served on the boards of two other public companies: Tesoro/Andeaver (2010-2018) and Celladon (2014-2016).

Judy Chou, Ph.D.

President and Chief Executive Officer

With over 20 years of experience in drug development and biomanufacturing, Dr. Judy Chou currently is the President, CEO, and Board member of AltruBio, Inc. Before taking on her current roles, she headed the global Biotech organization at Bayer Pharmaceuticals overseeing the development, manufacturing and distribution of Bayer’s $3+ billion per year biotechnology product portfolio & 2000+ employees and leading the drug development and launch activities for Biologics pipeline. In addition, she serves as the site head for Bayer’s facility in Berkeley, CA, which is the largest US manufacturing site in Bayer’s network. She is well recognized by the biomedical industry for her leadership and has received the Most Influential Women in Business Award in 2018 by San Francisco Business Times.

Before Bayer, Dr. Chou held the role of Vice President of Pharmaceutical /Technical Operations at Pfizer, Inc., formerly Medivation, where she led the Development and Manufacturing organizations for both biologics and small molecule products. She was also Vice President of R&D at Tanvex Biopharma, Inc., where Dr. Chou led the development of rich pipeline projects in R&D, manufacturing, and clinical development & operations to enable the success of the company’s IPO. Throughout Dr. Chou’s career, she has achieved significant milestones in protein therapeutic development and multiple filings of BLAs, NDAs, and INDs of novel products and is recognized for her work at Genentech, Pfizer (Wyeth) and Abbvie (Abbott) especially in the development of breakthrough technologies in analytical characterization and the accelerated product development.

Currently, Dr. Chou also serves as the Board of Directors of Akero Therapeutics, Inc. In addition, since 2017 she has been contributing to higher education through her role as an advisor of UC, Berkeley Engineering School, and promoting diversity and inclusion via her advisory board position at Silicon Valley Women in Engineering.

Before joining the industry, Dr. Chou was a research faculty member at Harvard University Medical School, focused on cell biology and neuroscience research. Dr. Chou obtained her Ph.D. from Yale University and completed her post-doctoral training at Max-Planck Institute in Germany.

Sean P. Bohen, M.D., Ph.D.

Dr. Sean Bohen is Preseident and Chief Executive Officer of Olema Oncology. Prior to joining Olema in 2021, he was executive vice president of global medicines development and chief medical officer at AstraZeneca from 2015 to 2019. He was responsible for AstraZeneca’s worldwide product development and clinical programs to address unmet medical needs and renew AstraZeneca's product pipeline.

Prior to joining AstraZeneca, he was Senior Vice President of Genentech Early Development from January, 2011. Dr. Bohen’s career at Genentech spanned 12 years. He joined Genentech in 2003 as Assistant Medical Director, Rituxan Heme/Onc. He was Associate Medical Director of Oncology Exploratory Clinical Development in 2004 and became Medical Director in 2005, then Associate Director in April, 2006. In October, 2006, he was Director of ITGR Exploratory Clinical Development and was promoted to Senior Director in October, 2007, then to Vice President of Immunology Development in August, 2008. In addition, Dr. Bohen also was an Adjunct Clinical Instructor in Oncology at Stanford University School of Medicine from 2002 to 2011.

He received his Bachelor of Science (Bacteriology) from University of Wisconsin-Madison, and M.D. and Ph.D. in Biochemistry from University of California, San Francisco.

John Doyle

John Doyle is chief financial officer of Aledade, Inc., a privately-held, health care technology business that sustains physician independence through value-based care.

Previously, John was chief executive officer and a member of the board of directors at Castlight Health, a publicly-held healthcare technology company, which he joined in 2012 as its chief financial officer. Prior to Castlight, John spent more than 20 years primarily in the biotechnology industry where he had most recently been the chief operating officer and then a member of the board of directors at Achaogen, a publicly-held firm focused on the development of life-saving antibiotics. Prior to Achaogen, John was vice president of business finance and corporate planning at Genentech.

John holds an MBA from the University of California, Berkeley, and received his undergraduate degree from California Polytechnic State University, San Luis Obispo. He is a member of the 2012 Class of Henry Crown Fellows at the Aspen Institute.

STEPHEN G. JUELSGAARD, D.V.M., J.D.

Stephen (“Steve”) Juelsgaard, is a former executive vice president, secretary and chief compliance officer of Genentech, Inc. He reported to Genentech’s CEO and was responsible for Genentech’s Corporate Law, Intellectual Property, Government Affairs (Federal and State), Human Resources, and Healthcare Compliance groups, as well as the Business Services group, which included Strategic Facilities Planning, Corporate Security, Business Continuity, and Environment, Health & Safety. He also chaired Genentech’s Capital Governance Committee, which oversaw major capital expenditures at the company and was a member of Genentech’s Executive Committee, the most senior management committee at the company. He served as secretary to Genentech’s Board of Directors and each of the Board’s Committees from 1997 to 2009. Dr. Juelsgaard’s career at Genentech spanned 24 years. He joined Genentech in 1985 as corporate counsel and became senior corporate counsel in 1989. In 1992 he became vice president, Corporate Law and in 1994 was named general counsel, a role he served in through 2007. He was named a senior vice president in 1998. In 2002, he was appointed executive vice president and in 2005 was named chief compliance officer. He was the company’s representative on the board of directors of the California Healthcare Institute from 2005 until 2009.

He left Genentech in 2009 when it became a wholly owned subsidiary of Roche. Prior to joining Genentech, he was an associate for three years with the law firm Wilson Sonsini Goodrich & Rosati in Palo Alto, California. Prior to attending law school, he was engaged for three years in a private veterinary medical (equine) practice in Southern California.

He is a member of the Independent Citizens Oversight Committee (board of directors) of the California Institute for Regenerative Medicine where he also is the chairman of the ICOC’s Intellectual Property and Industry Subcommittee and serves on the Application Review, Finance and Governance Subcommittees. He is also on the board of directors of Juvena Therapeutics and of the African Wildlife Foundation.

Dr. Juelsgaard received his Doctor of Veterinary Medicine degree from Iowa State University in 1972 and a Masters of Science degree in Veterinary Clinical Sciences in 1975 from Iowa State University where his research was focused on immunology. In 1982 he received a law degree from Stanford Law School.

Gur Roshwalb, M.D.

Dr. Gur Roshwalb is a Partner at aMoon, where he leads sourcing efforts, leads deals, manages the due diligence process, and sits on the board of MiNA Therapeutics, AltruBio and Viracta Therapeutics, aMoon Growth portfolio companies.

Beginning his career as a practicing physician, Gur understands the urgency driving the innovation in the healthcare industry. He moved to Israel in 2019 to work with aMoon to accelerate HealthTech advances into clinical practice. Gur has over 20 years of healthcare industry and finance experience. Prior to joining aMoon, he was CEO at several private and public biotech companies. Earlier, Gur was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in both private and public companies. Gur started his finance career at Piper Jaffray, where he worked as a vice president and equity analyst, publishing research on specialty pharmaceutical companies. Prior to Piper, Gur was in private practice in New York following residency training in internal medicine at Mount Sinai Medical Center, where he also served as Chief Resident.

Gur obtained his medical degree from Albert Einstein College of Medicine of Yeshiva University, his MBA from the NYU Stern School of Business, and a B.A. from Columbia University.

Corsee Sanders, Ph.D.

Corsee D. Sanders, Ph.D., was most recently the Strategic Advisor to the Celgene Office of the Chief Medical Officer. She was on the Executive Committee of Juno Therapeutics from January 2017 up to its acquisition by Celgene in 2018, reporting to the CEO and accountable for Quantitative Sciences, Project Leadership, Development Operations, and CAR T Patient Operations.

Prior to Juno, Dr. Sanders spent 7 years with Roche Pharmaceuticals in various roles, including Global Head of Biometrics, Global Head of Clinical Operations, and Global Head of Industry Collaborations. She was a member of the Late Stage Portfolio Committee, Co-chair of the Roche-Chugai Joint Portfolio Management Committee, and Vice-chair of the Board of Directors of TransCelerate Inc., on behalf of Roche. She spent 15 years with Genentech, Inc., prior to its acquisition by Roche, leading functions including Clinical and Nonclinical Biostatistics, Health Economics, Epidemiology, Real World Evidence, Business and Data Operations. Prior to that, she was a Biostatistics leader with Schering-Plough in NJ, and Centocor, Inc. in Malvern, PA. She started her career as a statistician with the Technical Board for Agricultural Credit, an arm of the Presidential Committee on Agricultural Credit in the Philippines.

Dr. Sanders holds Bachelor and Master of Science degrees in statistics from the University of the Philippines and a Ph.D. in Statistics from the Wharton Doctoral Programs of the University of Pennsylvania. Dr. Sanders is a member of the Board of Trustees at Fred Hutchinson Cancer Research Center and a board director of Molecular Templates, Legend Biotech, BeiGene and Ultragenyx.

Judy Chou, Ph.D.

President and Chief Executive Officer

With over 20 years of experience in drug development and biomanufacturing, Dr. Judy Chou currently is the President, CEO, and Board member of AltruBio, Inc. Before taking on her current roles, she headed the global Biotech organization at Bayer Pharmaceuticals overseeing the development, manufacturing and distribution of Bayer’s $3+ billion per year biotechnology product portfolio & 2000+ employees and leading the drug development and launch activities for Biologics pipeline. In addition, she serves as the site head for Bayer’s facility in Berkeley, CA, which is the largest US manufacturing site in Bayer’s network. She is well recognized by the biomedical industry for her leadership and has received the Most Influential Women in Business Award in 2018 by San Francisco Business Times.

Before Bayer, Dr. Chou held the role of Vice President of Pharmaceutical /Technical Operations at Pfizer, Inc., formerly Medivation, where she led the Development and Manufacturing organizations for both biologics and small molecule products. She was also Vice President of R&D at Tanvex Biopharma, Inc., where Dr. Chou led the development of rich pipeline projects in R&D, manufacturing, and clinical development & operations to enable the success of the company’s IPO. Throughout Dr. Chou’s career, she has achieved significant milestones in protein therapeutic development and multiple filings of BLAs, NDAs, and INDs of novel products and is recognized for her work at Genentech, Pfizer (Wyeth) and Abbvie (Abbott) especially in the development of breakthrough technologies in analytical characterization and the accelerated product development. Currently, Dr. Chou also serves as the Board of Directors of Akero Therapeutics, Inc. In addition, since 2017 she has been contributing to higher education through her role as an advisor of UC, Berkeley Engineering School, and promoting diversity and inclusion via her advisory board position at Silicon Valley Women in Engineering.

Before joining the industry, Dr. Chou was a research faculty member at Harvard University Medical School, focused on cell biology and neuroscience research. Dr. Chou obtained her Ph.D. from Yale University and completed her post-doctoral training at Max-Planck Institute in Germany.

Jeroen Grasman

Chief Financial Officer

Jeroen Grasman brings over 25 years of finance and operations experience to AltruBio. Before joining the company, he headed the financial operations at T-cell therapy company PACT Pharma, where he oversaw the finance, accounting, treasury and procurement functions as the organization grew from 25 to over 200 people, and supported the raise of a $90M series C as well as significant collaboration agreements.

Before PACT Pharma, he held the role of vice president of finance at Intarcia Therapeutics, where he led the effort to build the commercialization capabilities of the organization in anticipation of the launch of their lead asset. Prior to that, he spent 11 years with Genentech and Roche, holding finance leadership and executive positions across the research, development, manufacturing, business development, and corporate finance functions.

Mr. Grasman obtained his M.B.A. from Harvard Business School and completed his B.Sc. in Applied Mathematics at Groningen University.

Jesse W. Hall, MD

Chief Medical Officer

Dr. Hall is currently the Chief Medical Officer of AltruBio, Inc. Prior to joining AltruBio, he was Executive Vice President and Chief Medical Officer at Sublimity Therapeutics, a clinical-stage biotechnology company from 2018 to 2021. From 2013 to 2018, Dr. Hall served as an Executive Medical Director of Ardea Biosciences Inc., a biotechnology company. From 2009 to 2013, Dr. Hall held the position of Medical Director for Amgen Inc., a biopharmaceutical company. From 2004 to 2009, Dr. Hall held multiple positions of increasing responsibilities at Abbott Laboratories, a multinational medical devices and health care company.

Dr. Hall completed his B.A. in Ocean Studies and Economics from the University of San Diego and his M.D. from the College of Medicine at the University of Oklahoma.

Joseph S. McCracken, DVM, MS

Head of Business Development

Joe McCracken currently advises biopharmaceutical companies on the design and implementation of corporate strategy and business development initiatives; and serves on the Boards of Alkahest, Inc., EdiGENE Corporation, Kindred Biosciences, Regimmune Inc., and Savara Pharmaceuticals. Dr. McCracken was previously Vice President and Global Head of Business Development & Licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. From October 2009 until July 2011 he was General Manager, Roche Pharma Japan & Asia Regional Head, Roche Partnering. Prior to joining Roche Pharma, Dr. McCracken held the position of Vice President, Business Development at Genentech for 10 years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer.

Dr. McCracken holds a Bachelor of Science in Microbiology, a Master of Science in Pharmacology and a Doctorate in Veterinary Medicine from The Ohio State University.

Shih-Yao Lin, MD., Ph.D.

President of AltruBio Taiwan, Inc. and
Head of Clinical Development, AltruBio, Inc.

Prior to joining AltruBio, Dr. Lin was a research fellow (1998-2004) at Laboratory of Allergy and Immunology, Department of Experimental Pathology, Beth Israel Deaconess Medical Center in Boston, USA. Dr. Lin received his MD degree from School of Medicine, National Taiwan University, and completed the resident training at the Department of Laboratory Medicine, National Taiwan University Hospital. He also received the PhD degree (Immunology) from Centre d'Immunologie de Marseille-Luminy, University of Aix-Marseille II in Marseille, France.

Steve Flint

Vice President of Human Resources

Steve Flint is the Vice President of Human Resources of AltruBio. Steve has over 20 years of Human Resources leadership experience in biotechnology, pharmaceutical and research industries. He most recently served as the Site Head of the Human Resources function for Bayer Pharmaceuticals’ Berkeley and San Francisco, California sites with over 1,100 employees. Previously, he held roles of increasing responsibility at Impax Laboratories, Grifols Diagnostic Solutions, Inc., Perseid Therapeutics, Takeda Pharmaceuticals and The Salk Institute for Biological Studies.

Steve received his MBA, with an emphasis in International Management, from the University of San Diego and his Bachelor of Arts degree in Management from the University of Phoenix.

Gene Lee, Ph.D.

Vice President of Technical Development

Gene Lee has over 20 years of experience in the industry. Most recently, he was the Senior Director and global head of the Protein and Cell Sciences department at EMD Serono/Merck Healthcare, where he helped to oversee the early discovery and development of biologics and the pipeline transition to manufacturing. He also served as the US site head for the Discovery and Development Technologies organization at the Billerica, MA R&D facility. Prior to joining EMD Serono, Gene was the Director of Cell Line Generation at Percivia. He also worked at Wyeth BioPharma for 9 years in the cell line development group, contributing to a number of INDs and helping to advance the state of cell line technology and early process development.

Gene received his Bachelors degree in Biology from Carnegie-Mellon University, and his Ph.D. in Microbiology from NYU School of Medicine. He completed his post-doctoral training at the Dana-Farber Cancer Institute/Harvard Medical School in Boston, MA.

Leewen Lin, Ph.D., LL.M.

VP of Administration, AltruBio Taiwan and Head of Legal Affairs, AltruBio, Inc.

Prior to AltruBio, Dr. Lin had been Senior Staff Fellow in Center of Biologics Evaluation and Research, US Food and Drug Administration, Director of Biotechnology Development Program of Yung-Shin Pharmaceutical, and Vice President of BioTrust International Corporation. Dr. Lin had been a member of the Intellectual Property Committee of Academia Sinica, and served as an advisor to the Biotechnology and Pharmaceutical Promotion Group, Ministry of Economic Affairs, Taiwan, on legal and regulatory affairs.

Dr. Lin received her Ph.D. in Biochemistry from North Carolina State University, and obtained her postdoctoral training in Genetics and Molecular Biology in Harvard Medical School and Massachusetts General Hospital. In addition, she received her L.L.M at Soochow University Law School, Taipei, Taiwan.

Simona Reed, Ph.D.

Vice President of Clinical Operations

Prior to joining AltruBio Dr. Reed was a senior consultant at Genentech’s Pharma Technical Regulatory with the responsibilities in the global regulatory affairs of the marketed products lifecycle and portfolio management. Before that, Dr. Reed lead the Corporate Project Management and clinical operations at Tanvex BioPharma, and successfully directed several preclinical and clinical programs of the biosimilar products . Prior to that she was the regional commercial product launch manager at Teva/Allergan where she was responsible for the global product launch portfolio of over 100 generic products. Dr. Reed has commenced her career in the industry as a consultant at Washington Group International (London UK / Princeton NJ) where she managed number of projects for several global pharmaceutical companies, e.g. Grifols Los Angeles, CA, CSL Behring, Kankakee, IL, Bayer, Raleigh, NC, Gedeon Richter, Budapest, Hungary, Pfizer, Ringaskidy Ireland, Boehringer Ingelheim, Bracknell, UK.

Dr. Reed received her PhD degree in Enzyme Histochemistry from the Institute of Experimental Medicine, Czech Academy of Science in Prague, Czechia.

David T. Rubin, MD, AGAF, FACG, FASGE, FACP

Joseph B. Kirsner Professor of Medicine

Professor Rubin is a renowned gastroenterologist who specializes in the treatment and assessment of digestive diseases. He is the Joseph B. Kirsner Professor of Medicine at the University of Chicago, where he is also Chief of the Section of Gastroenterology, Hepatology and Nutrition, and co-director of the Digestive Diseases Center. His clinical expertise includes inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) and high-risk cancer syndromes.
Dr. Rubin received his Doctor of Medicine degree from the Pritzker School of Medicine, and did his residency and fellowship work at the University of Chicago. He also completed a fellowship at the University of Chicago MacLean Center for Clinical Medical Ethics.